Afficher la couverture 'Independent prognostic value of ultra-sensitive quantification of tumor pre-treatment T790M subclones in EGFR mutated non-small cell lung cancer (NSCLC) treated by first/second generation TKI, depends on variant allele frequency (VAF): Results of the French cooperative thoracic intergroup (IFCT) biomarkers France project | Beau-Faller, Michèle' en grand format
/5

0 avis

Independent prognostic value of ultra-sensitive quantification of tumor pre-treatment T790M subclones in EGFR mutated non-small cell lung cancer (NSCLC) treated by first/second generation TKI, depends on variant allele frequency (VAF): Results of the French cooperative thoracic intergroup (IFCT) biomarkers France project

Archive ouverte

Beau-Faller, Michèle | Pencreach, Erwan | Leduc, Charlotte | Blons, Hélène | Merlio, Jean-Philippe | Bringuier, Pierre-Paul | de Fraipont, Florence | Escande, Fabienne | Lemoine, Antoinette | Ouafik, L'Houcine | Denis, Marc, G. | Hofman, Paul | Lacave, Roger | Melaabi, Samia | Langlais, Alexandra | Missy, Pascale | Morin, Franck | Moro-Sibilot, Denis | Barlesi, Fabrice | Cadranel, Jacques

Edité par CCSD ; Elsevier -

International audience. T790M mutations inEGFR-mutated non-small cell lung cancer (NSCLC) account for nearly 50% of acquired resistance mechanisms to EGFR-TKIs. Earlier studies suggested that tumor T790M could also be detected in TKI-naïve EGFR-mutated NSCLC. The aim of the study is to assess the prevalence and clinical significance of quantification of tumor pre-treatment T790M subclones.

Suggestions

Du même auteur

Independent prognostic value of ultra-sensitive quantification of tumor pre-treatment T790M subclones in EGFR mutated non-small cell lung cancer (NSCLC) treated by first/second generation TKI, depends on variant allele frequency (VAF): Results of the French cooperative thoracic intergroup (IFCT) biomarkers France project

Archive ouverte | Beau-Faller, Michèle | CCSD

International audience. T790M mutations inEGFR-mutated non-small cell lung cancer (NSCLC) account for nearly 50% of acquired resistance mechanisms to EGFR-TKIs. Earlier studies suggested that tumor T790M could also ...

Routine molecular profiling of cancer: results of a one-year nationwide program of the French Cooperative Thoracic Intergroup (IFCT) for advanced non-small cell lung cancer (NSCLC) patients.

Archive ouverte | Barlesi, Fabrice | CCSD

International audience. Background: The molecular profiling of patients with advanced non-small-cell lung cancer (NSCLC) for known oncogenic drivers is recommended during routine care. Nationally, however, the feasi...

Outcomes of Patients With Advanced NSCLC From the Intergroupe Francophone de Cancérologie Thoracique Biomarkers France Study by KRAS Mutation Subtypes

Archive ouverte | Ruppert, Anne-Marie | CCSD

International audience. Introduction - Methods - In the Biomarkers France study, 4894 mutations (26.2%) were detected in 4634 patients from the 17,664 enrolled patients with NSCLC. Survival and treatment data on no...

Chargement des enrichissements...